"Ovid Therapeutics recently reported its second-quarter 2025 financial results, highlighting a $7 million royalty monetization agreement, which contributed to a notable 34.92% increase in share price. However, the company faces ongoing risks related to its financial performance and market position, reflected in a low average sentiment score of 0.23."